Back to resultsComputer-assisted Risk Evaluation in the Early Detection of Psychotic Disorders (CARE)
Primary Purpose
Psychotic Disorders, Prevention
Status
Recruiting
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
"pronia.ai" medical device for high risk psychosis prognosis
Treatment-as-usual (TAU)
Sponsored by
About this trial
This is an interventional prevention trial for Psychotic Disorders focused on measuring Psychosis-Risk Syndromes, high-risk, Cognitive Disturbances, Artificial Intelligence
Eligibility Criteria
Inclusion Criteria: The increased risk of psychosis includes either a symptomatic "ultra high-risk" stage of the Structured Interview for Psychosis-Risk Syndromes or the "Cognitive Disturbances" risk criterion of the Schizophrenia Proneness Instrument - Children and Youth and Adult versions ages 16 to 40 Presence of a written Exclusion Criteria: manifest psychosis (ICD-10 F2x.x, F3x.3) according to the definition of the Structured Interview for Psychosis-Risk Syndromes . Lack of capacity to give consent (the patient lacks the capacity to consent if the individual case with regard to the specific treatment measure is excluded. Only when the physician has concrete indications that that the patient's capacity to consent may be lacking, he may and must must examine it. Mental disorders (e.g. delirium, dementia, psychosis, mania, depression) or cognitive impairments can have an influence on the capacity to consent. Indications for doubts of a ability to give informed consent exist if the physician has the impression that the patient is not able to understand the provided patient information and is not able to reproduce essential information about the study in his or her own words and is not aware of the possible consequences of the proposed measures Severe suicidality during the recruitment phase (CDSS items 8 ≥2) A current or past neurological disease of the brain. a current or past known somatic disease that potentially affects the structure or function of the brain Antipsychotic medication for >30 days (cumulative number of days). At or above the minimum dose for a psychotic first episode according to the the German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN) S3 guidelines an antipsychotic medication in the 3 months prior to baseline. (regardless of the length of time taken) at or above the minimum dose for a psychotic first episode according to the DGPPN S3-guidelines An inadequate level of hearing for neurocognitive testing a current or past head trauma with unconsciousness (>5 min.; a current or past alcohol dependence (ICD-10 F10.x) A current polytoxicomania (multiple substance dependence) or polytoxicomania in the past 6 months (ICD-10 F19.x) Presence of medical reasons that contraindicate performance of an MRI Insufficient language skills to understand the indication and the purpose of the intended examinations and interventions stationary accommodation against the patient's will
Sites / Locations
- ZfP Reichenau - Akademisches Lehrkrankenhaus Universität KonstanzRecruiting
- Zentralinstitut für Seelische GesundheitRecruiting
- Klinik für Psychiatrie und Psychotherapie Universität TübingenRecruiting
- Klinikum der Ludwig-Maximilians-Universität MünchenRecruiting
- Zentrum für psychische Gesundheit, U11iversitätsklinikum WürzburgRecruiting
- Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Universitätsklinikum Aachen, RWTH Universität AachenRecruiting
- LWL-Universitätsklinikum Bochum der Ruhr--Universität Bochum, Klinik für Psychiatrie, Psychotherapie und PräventivmedizinRecruiting
- KJPP LVR-Klinik Bon'nRecruiting
- Universitätsklinikum Bonn Klinik für Psychiatrie und PsychotherapieRecruiting
- Klinik und Poliklinik für Psychiatrie und Psychotherapie Heinrich-Heine-Universität DüsseldorfRecruiting
- Uniklinik Köln, Klinik und Poliklin-ik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und JugendaltersRecruiting
- Institut für Translationale PsychiatrieRecruiting
- Rheinhessen Fachklinik AlzeyRecruiting
- Otto-von-Guericke- Universität MagdeburgRecruiting
- UKD Dresden, Klinik und Poliklinik für Psychiatrie und Psychotherapie
- Zentrum für Integrative Psychiatrie KielRecruiting
- Zentrum für Integrative Psychiatrie (ZIP) und Fachklinik für Junges Leben (JuLe) Kinder- und JugendpsychiatrieRecruiting
- Vivantes Klinikum Am UrbanRecruiting
- Charité - Universitätsmedizin BerlinRecruiting
- Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Hamburg-Eppendorf {UKE)Recruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
CARE interventional treatment
Standard of Care Control arm
Arm Description
AI-computerassisted prognosis of high risk psychosis profile and adapted study-specific therapy taking place in early-recognition centers.
Treatment as usual (TAU) patient will receive their usual treatment from their local physicians and therapeutic personnel.
Outcomes
Primary Outcome Measures
Structured Interview for Psychosis-Risk Syndromes (SIPS)
Presence of psychotic syndrome (POPS) criteria as modified according to the "PRONIA" study, resulting in a score of 0= "no psychosis" or 1= "psychosis"
Secondary Outcome Measures
Internalized Stigma of Mental Illness Scale (ISMI)
Consisting of 5-subscales, comprising of 29 items in total using response formats varying from 4-point Likert scales (1='not at all', 4='very often') to 5-point Likert scales (1='never', 5='very often'), assessing self-stigma in terms of alienation, adoption of stereotypes, experiences of discrimination, social withdrawal and stigma resistance.
Stigma-Stress-Scale
two dimensions are assessed, 8 items are rated on a 5-point Likert-scale from "strongly disagree" to "totally agree", capturing self-assessed-stigma stress.
Self-Identification of Mental Illness Scale (SELF-I)
5-point Likert-scale ranging from 1 = "not true at all" to 5 = " is completely true", capturing the degree of self-identification with mental illnesses.
Coming-Out with Mental Illness Scale (COMIS)
consisting of two subscales with 7 and 14 items, each with 7-step Likert-scale ranging from 1 = "do not agree at all" to 7 = " totally agree", capturing a potential change of strategies for dealing with mental illness.
Secrecy and disclosure-related distress - scale
7-point single-item-scale ranging from 1 = " not at all" to 7 = "very much", measuring the degree of subjective stress.
Psychosis own health-concern single score
5-point Likert-scale ranging from 1 = "not at all" to 5 = "strong", capturing the degree of self-concern in terms of getting a psychosis one day.
Numeracy Scale
A single score from 0 to 100% indicating the patient self-estimated amount of belief in risk for developing psychosis within the next 12 months.
Coping (Ten-Flex)
Patient self-estimation of likelihood for developing psychosis given on a visual analogue scale (VAS) indicating "I will not develop psychosis in the next 12 months" on the left side of the scale up to "I will definitely develop psychosis in the next 12 months" on the right side of the scale.
Risk Perception Scale
A score from 1 =no risk" to 7 = "absolutely certain" indicating the risk for developing psychosis.
Risk Recall Scale
A score from 1 = "much lower" to 5 "much higher" indicating the risk for developing psychosis compared to a healthy peer.
Health-related quality of life (EQ-5D)
patient questionnaire consisting of two sub-scores. a) score from 0-10 whereas a higher score indicates greater impairment; b) score from 0-100 whereas a higher score indicates better current health status to measure the quality of Life.
Brief Multidimensional Life Satisfaction Scale (BMLSS)
Score from 0-126, a higher score indicates a higher amount of satisfaction.
Client Sociodemographic and Service Receipt Inventory (CSSRI-EU)
Changes in service use are measured with a semi-structured interview to assess social and demographic data, accommodation data, detailed information regarding treatment, professional visits and social and health service utilization for estimating healthcare costs. Additionally, the CSSRI systematically records the use of psychiatric, medical, psycho-social and rehabilitative health services (direct costs) and productivity losses (indirect costs) and therefore completely covers the costs of the disease from an economic perspective.
Patient Satisfaction Questionnaire (ZUF-8)
8 Items with a total score of 8-32, ranging from 4 = "very satisfied" to 1="fairly satisfied" whereas a higher score indicates higher patient satisfaction.
Social and occupational assessment scale SOFAS
Scores from 0-100, a higher score indicates better social functioning.
Global Functioning Social Scale (GF:S)
Scores from 1-10, a higher score indicates better global functioning
Global Functioning Role Scale (GF:R)
Scores from 1-10, a higher score indicates better functioning
Secrecy-Symptoms Scale
Five questions (either yes or no) asking who the patient has told about the risk for developing psychosis
Full Information
NCT ID
NCT05813080
First Posted
March 14, 2023
Last Updated
August 2, 2023
Sponsor
Heinrich-Heine University, Duesseldorf
1. Study Identification
Unique Protocol Identification Number
NCT05813080
Brief Title
Computer-assisted Risk Evaluation in the Early Detection of Psychotic Disorders
Acronym
CARE
Official Title
Computer-assisted Risk Evaluation in the Early Detection of Psychotic Disorders
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 1, 2023 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
March 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Heinrich-Heine University, Duesseldorf
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Multicenter randomized controlled trial (RCT) with artificial intelligence (AI)-staged early diagnostics and risk-adapted treatment (RAB) as interventional treatment arm and treatment-as-usual (TAU) as control treatment arm for patients with an increased clinical risk for psychosis.
Detailed Description
The study is a Investigator Initiated Trial (IIT)/Other clinical trial of a class 2a medical device according to article 82 medical devices regulation of the European Union.
The aim of risk-adapted treatment (RAB) arm is to reduce the number of patients with an increased clinical risk for psychosis (ICD-10: schizophrenic disorders F2x.x, affective disorders F3x.3) to actually develop a manifest psychosis.
Patients assigned to the active treatment arm will receive additional in-depth clinical diagnostics including neuropsychological testing.
The AI-supported algorithm "pronia.ai" uses information from both the individual patient data of the specialized routine diagnostics as well as from in-depth clinical diagnostics.
There are two predictions, an individual quantitative assessment of the individual risk of transition to psychosis and the individual prognosis with regard to the level of psychosocial functioning 12 months after inclusion in the study.
The therapists and patients receive a non-binding risk profile from the AI-based recommendation to adjust the treatment intensity from 16 to 24 sessions over a period of six months.
The cognitive behavioral therapy-based manual "Integrated Preventive Psychological Preventive Psychological Intervention (IPPI)" manual is used. In the treatment-as-usual arm (TAU),the patients receive referral back to the previous care system; further treatment (and additional diagnostics, if necessary) is left to the referring primary care providers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Psychotic Disorders, Prevention
Keywords
Psychosis-Risk Syndromes, high-risk, Cognitive Disturbances, Artificial Intelligence
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The aim of risk-adapted treatment (RAB) arm is to reduce the number of patients with an increased clinical risk for psychosis (ICD-10: schizophrenic disorders F2x.x, affective disorders F3x.3) to actually develop a manifest psychosis.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
436 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
CARE interventional treatment
Arm Type
Experimental
Arm Description
AI-computerassisted prognosis of high risk psychosis profile and adapted study-specific therapy taking place in early-recognition centers.
Arm Title
Standard of Care Control arm
Arm Type
Active Comparator
Arm Description
Treatment as usual (TAU) patient will receive their usual treatment from their local physicians and therapeutic personnel.
Intervention Type
Device
Intervention Name(s)
"pronia.ai" medical device for high risk psychosis prognosis
Intervention Description
In addition to the computer-assisted prognosis of risk for reaching a psychosis, all patients assigned to the active treatment arm will receive additional in-depth clinical diagnostics including neuropsychological testing. Adapted psychological treatment will be offered consisting of 16 to 24 sessions over a period of six months.
Intervention Type
Other
Intervention Name(s)
Treatment-as-usual (TAU)
Intervention Description
Referral back to the previous care system. Further treatment is left to the referring primary care providers.
Primary Outcome Measure Information:
Title
Structured Interview for Psychosis-Risk Syndromes (SIPS)
Description
Presence of psychotic syndrome (POPS) criteria as modified according to the "PRONIA" study, resulting in a score of 0= "no psychosis" or 1= "psychosis"
Time Frame
12-month after inclusion
Secondary Outcome Measure Information:
Title
Internalized Stigma of Mental Illness Scale (ISMI)
Description
Consisting of 5-subscales, comprising of 29 items in total using response formats varying from 4-point Likert scales (1='not at all', 4='very often') to 5-point Likert scales (1='never', 5='very often'), assessing self-stigma in terms of alienation, adoption of stereotypes, experiences of discrimination, social withdrawal and stigma resistance.
Time Frame
12-month after inclusion
Title
Stigma-Stress-Scale
Description
two dimensions are assessed, 8 items are rated on a 5-point Likert-scale from "strongly disagree" to "totally agree", capturing self-assessed-stigma stress.
Time Frame
12-month after inclusion
Title
Self-Identification of Mental Illness Scale (SELF-I)
Description
5-point Likert-scale ranging from 1 = "not true at all" to 5 = " is completely true", capturing the degree of self-identification with mental illnesses.
Time Frame
12-month after inclusion
Title
Coming-Out with Mental Illness Scale (COMIS)
Description
consisting of two subscales with 7 and 14 items, each with 7-step Likert-scale ranging from 1 = "do not agree at all" to 7 = " totally agree", capturing a potential change of strategies for dealing with mental illness.
Time Frame
12-month after inclusion
Title
Secrecy and disclosure-related distress - scale
Description
7-point single-item-scale ranging from 1 = " not at all" to 7 = "very much", measuring the degree of subjective stress.
Time Frame
12-month after inclusion
Title
Psychosis own health-concern single score
Description
5-point Likert-scale ranging from 1 = "not at all" to 5 = "strong", capturing the degree of self-concern in terms of getting a psychosis one day.
Time Frame
12-month after inclusion
Title
Numeracy Scale
Description
A single score from 0 to 100% indicating the patient self-estimated amount of belief in risk for developing psychosis within the next 12 months.
Time Frame
12-month after inclusion
Title
Coping (Ten-Flex)
Description
Patient self-estimation of likelihood for developing psychosis given on a visual analogue scale (VAS) indicating "I will not develop psychosis in the next 12 months" on the left side of the scale up to "I will definitely develop psychosis in the next 12 months" on the right side of the scale.
Time Frame
12-month after inclusion
Title
Risk Perception Scale
Description
A score from 1 =no risk" to 7 = "absolutely certain" indicating the risk for developing psychosis.
Time Frame
12-month after inclusion
Title
Risk Recall Scale
Description
A score from 1 = "much lower" to 5 "much higher" indicating the risk for developing psychosis compared to a healthy peer.
Time Frame
12-month after inclusion
Title
Health-related quality of life (EQ-5D)
Description
patient questionnaire consisting of two sub-scores. a) score from 0-10 whereas a higher score indicates greater impairment; b) score from 0-100 whereas a higher score indicates better current health status to measure the quality of Life.
Time Frame
12-month after inclusion
Title
Brief Multidimensional Life Satisfaction Scale (BMLSS)
Description
Score from 0-126, a higher score indicates a higher amount of satisfaction.
Time Frame
12-month after inclusion
Title
Client Sociodemographic and Service Receipt Inventory (CSSRI-EU)
Description
Changes in service use are measured with a semi-structured interview to assess social and demographic data, accommodation data, detailed information regarding treatment, professional visits and social and health service utilization for estimating healthcare costs. Additionally, the CSSRI systematically records the use of psychiatric, medical, psycho-social and rehabilitative health services (direct costs) and productivity losses (indirect costs) and therefore completely covers the costs of the disease from an economic perspective.
Time Frame
12-month after inclusion
Title
Patient Satisfaction Questionnaire (ZUF-8)
Description
8 Items with a total score of 8-32, ranging from 4 = "very satisfied" to 1="fairly satisfied" whereas a higher score indicates higher patient satisfaction.
Time Frame
12-month after inclusion
Title
Social and occupational assessment scale SOFAS
Description
Scores from 0-100, a higher score indicates better social functioning.
Time Frame
12-month after inclusion
Title
Global Functioning Social Scale (GF:S)
Description
Scores from 1-10, a higher score indicates better global functioning
Time Frame
12-month after inclusion
Title
Global Functioning Role Scale (GF:R)
Description
Scores from 1-10, a higher score indicates better functioning
Time Frame
12-month after inclusion
Title
Secrecy-Symptoms Scale
Description
Five questions (either yes or no) asking who the patient has told about the risk for developing psychosis
Time Frame
12-month after inclusion
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The increased risk of psychosis includes either a symptomatic "ultra high-risk" stage of the Structured Interview for Psychosis-Risk Syndromes or the "Cognitive Disturbances" risk criterion of the Schizophrenia Proneness Instrument - Children and Youth and Adult versions
ages 16 to 40
Presence of a written
Exclusion Criteria:
manifest psychosis (ICD-10 F2x.x, F3x.3) according to the definition of the Structured Interview for Psychosis-Risk Syndromes .
Lack of capacity to give consent (the patient lacks the capacity to consent if the individual case with regard to the specific treatment measure is excluded. Only when the physician has concrete indications that that the patient's capacity to consent may be lacking, he may and must must examine it. Mental disorders (e.g. delirium, dementia, psychosis, mania, depression) or cognitive impairments can have an influence on the capacity to consent. Indications for doubts of a ability to give informed consent exist if the physician has the impression that the patient is not able to understand the provided patient information and is not able to reproduce essential information about the study in his or her own words and is not aware of the possible consequences of the proposed measures
Severe suicidality during the recruitment phase (CDSS items 8 ≥2)
A current or past neurological disease of the brain.
a current or past known somatic disease that potentially affects the structure or function of the brain
Antipsychotic medication for >30 days (cumulative number of days). At or above the minimum dose for a psychotic first episode according to the the German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN) S3 guidelines
an antipsychotic medication in the 3 months prior to baseline. (regardless of the length of time taken) at or above the minimum dose for a psychotic first episode according to the DGPPN S3-guidelines
An inadequate level of hearing for neurocognitive testing
a current or past head trauma with unconsciousness (>5 min.; a current or past alcohol dependence (ICD-10 F10.x)
A current polytoxicomania (multiple substance dependence) or polytoxicomania in the past 6 months (ICD-10 F19.x)
Presence of medical reasons that contraindicate performance of an MRI
Insufficient language skills to understand the indication and the purpose of the intended examinations and interventions
stationary accommodation against the patient's will
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sarah Maciej, Dr.
Phone
+49 211 81 16263
Email
sarah.maciej@med.uni-duesseldorf.de
First Name & Middle Initial & Last Name or Official Title & Degree
Christian Calles, Dr.
Phone
+49 211 81 16149
Email
christian.calles@med.uni-duesseldorf.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eva Meisenzahl-Lechner, Prof.
Organizational Affiliation
Klinik und Poliklinik für Psychiatrie und Psychotherapie LVR-Klinikum Düsseldorf
Official's Role
Principal Investigator
Facility Information:
Facility Name
ZfP Reichenau - Akademisches Lehrkrankenhaus Universität Konstanz
City
Konstanz
State/Province
Baden-Württemberg
ZIP/Postal Code
78479
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Simon Senner, Dr.
Email
S.Senner@zfp-reichenau.de
Facility Name
Zentralinstitut für Seelische Gesundheit
City
Mannheim
State/Province
Baden-Württemberg
ZIP/Postal Code
68159
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dusan Hirjak, Prof.
Email
Dusan.Hirjak@zi-mannheim.de
Facility Name
Klinik für Psychiatrie und Psychotherapie Universität Tübingen
City
Tübingen
State/Province
Baden-Württemberg
ZIP/Postal Code
72076
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andreas Fallgatter, Prof.
Email
Andreas.Fallgatter@med.uni-tuebingen.de
Facility Name
Klinikum der Ludwig-Maximilians-Universität München
City
München
State/Province
Bayern
ZIP/Postal Code
80336
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Selina Kornbichler, Dr. med.
Email
elina.Kornbichler@med.uni-muenchen.de
Facility Name
Zentrum für psychische Gesundheit, U11iversitätsklinikum Würzburg
City
Würzburg
State/Province
Bayern
ZIP/Postal Code
97080
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Barbara Hütz, Dr. med.
Email
Huetz_B@ukw.de
Facility Name
Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Universitätsklinikum Aachen, RWTH Universität Aachen
City
Aachen
State/Province
NRW
ZIP/Postal Code
52074
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Frodl, Prof.
Email
Thomas.Frodl@med.ovgu.de
Facility Name
LWL-Universitätsklinikum Bochum der Ruhr--Universität Bochum, Klinik für Psychiatrie, Psychotherapie und Präventivmedizin
City
Bochum
State/Province
NRW
ZIP/Postal Code
44791
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Georg Juckel, Prof.
Email
georg.juckel@rub.de
Facility Name
KJPP LVR-Klinik Bon'n
City
Bonn
State/Province
NRW
ZIP/Postal Code
53111
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ulf Thiemann, Dr. med.
Email
Ulf.Thiemann@lvr.de
Facility Name
Universitätsklinikum Bonn Klinik für Psychiatrie und Psychotherapie
City
Bonn
State/Province
NRW
ZIP/Postal Code
53127
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexandra Philipsen, Prof.
Email
Alexandra.philipsen@ukbonn.de
Facility Name
Klinik und Poliklinik für Psychiatrie und Psychotherapie Heinrich-Heine-Universität Düsseldorf
City
Düsseldorf
State/Province
NRW
ZIP/Postal Code
40629
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eva Meisenzahl, Prof.
Phone
0211/922- 2001
Email
Eva.Meisenzahl@lvr.de
Facility Name
Uniklinik Köln, Klinik und Poliklin-ik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters
City
Köln
State/Province
NRW
ZIP/Postal Code
50931
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephan Bender, Prof.
Email
stephan.bender@uk-koeln.de
First Name & Middle Initial & Last Name & Degree
Joseph Kambeitz, Prof.
Email
joseph.kambeitz@uk-koeln.de
Facility Name
Institut für Translationale Psychiatrie
City
Münster
State/Province
NRW
ZIP/Postal Code
48149
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Udo Dannlowski, Prof.
Email
udo.dannlowski@ukmuenster.de
Facility Name
Rheinhessen Fachklinik Alzey
City
Alzey
State/Province
Rheinland-Pfalz
ZIP/Postal Code
55232
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Huss, Prof.
Email
m.huss@rfk.landeskrankenhaus.de
Facility Name
Otto-von-Guericke- Universität Magdeburg
City
Magdeburg
State/Province
Sachsen-Anhalt
ZIP/Postal Code
39120
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Johann Steiner, Prof.
Email
johann.steiner@med.ovgu.de
Facility Name
UKD Dresden, Klinik und Poliklinik für Psychiatrie und Psychotherapie
City
Dresden
State/Province
Sachsen
ZIP/Postal Code
01307
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Pfennig, Prof.
Email
Andrea.Pfennig@ukdd.de
Facility Name
Zentrum für Integrative Psychiatrie Kiel
City
Kiel
State/Province
Schleswig-Holstein
ZIP/Postal Code
24105
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Manuel Munz, Dr. med.
Email
Manuel.Munz@uksh.de
Facility Name
Zentrum für Integrative Psychiatrie (ZIP) und Fachklinik für Junges Leben (JuLe) Kinder- und Jugendpsychiatrie
City
Lübeck
State/Province
Schleswig-Holstein
ZIP/Postal Code
23554
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Lipp, Dr.
Email
Michael.Lipp@vorwerker-diakonie.de
Facility Name
Vivantes Klinikum Am Urban
City
Berlin
ZIP/Postal Code
10967
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andreas Bechdolf, Prof.
Email
Andreas.Bechdolf@vivantes.de
Facility Name
Charité - Universitätsmedizin Berlin
City
Berlin
ZIP/Postal Code
13353
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christoph Correll, Prof.
Email
Christoph.Correll@charite.de
Facility Name
Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Hamburg-Eppendorf {UKE)
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Lambert, Prof.
Email
lambert@uke.de
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Computer-assisted Risk Evaluation in the Early Detection of Psychotic Disorders
We'll reach out to this number within 24 hrs